Perspective Chapter: Pharmaceutical Drying

This chapter presents an overview of the perspective chapter on pharmaceutical drying within the context of drug manufacturing. It explores the significance of pharmaceutical drying in ensuring the stability and efficacy of drug products. The chapter begins by defining pharmaceutical drying and emphasizing its importance in the manufacturing process. Various methods of pharmaceutical drying, including air drying, vacuum drying, freeze-drying, and spray drying, are discussed, and a comparison between these methods is provided. Factors that influence pharmaceutical drying, such as physical and chemical properties of the product, drying temperature, drying time, pressure, humidity, and solvent properties, are examined. The chapter also highlights the challenges associated with pharmaceutical drying, including product stability and degradation, loss of potency, residual solvents, and the formation of amorphous or crystalline solids. Strategies to overcome these challenges, such as process optimization, the use of drying aids, control of drying parameters, and formulation considerations, are explored. Quality control measures in pharmaceutical drying, including the monitoring of residual moisture and solvent levels, characterization of dried products, and adherence to regulatory guidelines, are discussed

DESIGN OF POTENT ANTICANCER MOLECULES COMPRISING PYRAZOLYL- THIAZOLINONE ANALOGUES BY USING MOLECULAR MODELLING STUDIES FOR PHARMACOPHORE OPTIMIZATION

Objectives: Numerous tiny Receptor Tyrosine Kinase Inhibitors have been reported as anticancer medications over the past ten years. However, a lot of them lack effectiveness in vivo, selectivity, or don't last long before developing resistance. Methods: We used molecular modelling research to improve the pharmacophore in order to get beyond these limitations. For the purpose of linking the chemical makeup of pyrazolyl thiazolinone analogues with their anticancer activity, quantitative structure activity relationship (QSAR) investigations in two dimensions (2D) and three dimensions (3D) were carried out. Pyrazolyl thiazolinone pharmacophore's stearic, electronic, and hydrophobic requirements were calculated using 3D QSAR. Results: By leveraging the findings of QSAR investigations, the pharmacophore was refined and new chemical entities (NCEs) were generated. The r2 and q2 values obtained for the best model No. 4 of 2D QSAR were 0.9244 and 0.8701, respectively. A drug-like pharmacokinetic profile was ensured by studying the binding affinities of proposed NCEs on EGFR-TK using docking studies and estimating their distribution, metabolism, absorption, and excretion (ADME) features. Conclusion: When statistical significance is closely examined, predictability of the model and its residuals (actual activity minus predicted activity) are found to be close to zero, leading us to draw the conclusion that the logic behind the design of new chemical entities was determined to be sound